Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds
- 25 January 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (6) , 1558-1573
Abstract
Purpose Classical brachytherapy of solid malignant tumors is an invasive procedure which often results in an uneven dose distribution, while requiring surgical removal of sealed radioactive seed sources after a certain period of time. To circumvent these issues, we report the synthesis of intrinsically radiolabeled and gum Arabic glycoprotein functionalized [169Yb]Yb2O3 nanoseeds as a novel nanoscale brachytherapy agent, which could directly be administered via intratumoral injection for tumor therapy. Methods 169Yb (T½ = 32 days) was produced by neutron irradiation of enriched (15.2% in 168Yb) Yb2O3 target in a nuclear reactor, radiochemically converted to [169Yb]YbCl3 and used for nanoparticle (NP) synthesis. Intrinsically radiolabeled NP were synthesized by controlled hydrolysis of Yb3+ ions in gum Arabic glycoprotein medium. In vivo SPECT/CT imaging, autoradiography, and biodistribution studies were performed after intratumoral injection of radiolabeled NP in B16F10 tumor bearing C57BL/6 mice. Systematic tumor regression studies and histopathological analyses were performed to demonstrate therapeutic efficacy in the same mice model. Results The nanoformulation was a clear solution having high colloidal and radiochemical stability. Uniform distribution and retention of the radiolabeled nanoformulation in the tumor mass were observed via SPECT/CT imaging and autoradiography studies. In a tumor regression study, tumor growth was significantly arrested with different doses of radiolabeled NP compared to the control and the best treatment effect was observed with ~ 27.8 MBq dose. In histopathological analysis, loss of mitotic cells was apparent in tumor tissue of treated groups, whereas no significant damage in kidney, lungs, and liver tissue morphology was observed. Conclusions These results hold promise for nanoscale brachytherapy to become a clinically practical treatment modality for unresectable solid cancers. Graphical AbstractKeywords
Funding Information
- Bhabha Atomic Research Centre
- Office of Extramural Research (P30 CA014520, T32 CA009206)
This publication has 56 references indexed in Scilit:
- Raman spectra of RE2O3 (RE=Eu, Gd, Dy, Ho, Er, Tm, Yb, Lu, Sc and Y): laser-excited luminescence and trace impurity analysisJournal of Rare Earths, 2014
- Anharmonic behavior and structural phase transition in Yb2O3AIP Advances, 2013
- Matching chelators to radiometals for radiopharmaceuticalsChemical Society Reviews, 2013
- Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian CancerJournal of Nuclear Medicine, 2012
- Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancerProceedings of the National Academy of Sciences, 2012
- The global burden of cancer: priorities for preventionCarcinogenesis, 2009
- ‘Two is better than one’—probes for dual-modality molecular imagingChemical Communications, 2009
- XPS studies of the intermediate valence state of Yb in (YbS)1.25CrS2Journal of Electron Spectroscopy and Related Phenomena, 2008
- Cross-section measurement of the 169Tm(p,n) reaction for the production of the therapeutic radionuclide 169Yb and comparison with its reactor-based generationApplied Radiation and Isotopes, 2005
- Correlation of spectral and heat-capacity Schottky contributions for Dy2O3, Er2O3, and Yb2O3The Journal of Chemical Physics, 1982